Financial Contrast: Scpharmaceuticals (SCPH) versus Its Rivals

Share on StockTwits

Scpharmaceuticals (NASDAQ: SCPH) is one of 497 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Scpharmaceuticals to related businesses based on the strength of its profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Scpharmaceuticals and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scpharmaceuticals 0 0 3 0 3.00
Scpharmaceuticals Competitors 3128 9471 22565 680 2.58

Scpharmaceuticals presently has a consensus target price of $12.67, indicating a potential upside of 121.83%. As a group, “Pharmaceutical preparations” companies have a potential upside of 42.90%. Given Scpharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Scpharmaceuticals is more favorable than its rivals.

Valuation & Earnings

This table compares Scpharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Scpharmaceuticals N/A -$23.81 million -0.71
Scpharmaceuticals Competitors $2.00 billion $130.71 million -3.12

Scpharmaceuticals’ rivals have higher revenue and earnings than Scpharmaceuticals. Scpharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

44.9% of Scpharmaceuticals shares are owned by institutional investors. Comparatively, 47.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 4.8% of Scpharmaceuticals shares are owned by company insiders. Comparatively, 15.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Scpharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Scpharmaceuticals N/A N/A N/A
Scpharmaceuticals Competitors -2,968.95% -161.14% -30.85%

Summary

Scpharmaceuticals beats its rivals on 7 of the 12 factors compared.

Scpharmaceuticals Company Profile

scPharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting. Its product pipeline also includes scFurosemide, a loop diuretic for the management of edema in patients with decompensated heart failure; scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.